SCHEMBL3762828

SCHEMBL3762828

O=C(CN1CCN(C(=O)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC1)N1CCN(C2CCC2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHOC P08134 2/20 0.48
RHOA P61586 2/20 0.48
HRH3 Q9Y5N1 4/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ALDH1A1 P00352 2/20 0.46
MAPT P10636 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
L3MBTL3 Q96JM7 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TSHR P16473 3/20 0.44
CYP2C9 P11712 2/20 0.44
HIF1A Q16665 1/20 0.44
PKM P14618 1/20 0.43
USP2 O75604 4/20 0.43
CYP3A4 P08684 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
KDM4E B2RXH2 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3773869 0.89 POLB (0.57) HRH3MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3767394 0.89 HRH3 (0.56) HRH3MEN1KMT2AALDH1A1L3MBTL3
SCHEMBL3764970 0.82 KDM4E (0.53) HRH3ALDH1A1L3MBTL3L3MBTL1PKM
SCHEMBL3770028 0.82 HPGD (0.50) HRH3ALDH1A1NPSR1L3MBTL3L3MBTL1
SCHEMBL3767937 0.81 ALDH1A1 (0.48) HRH3MEN1KMT2AALDH1A1MAPT
SCHEMBL3770306 0.81 KMT2A (0.51) HRH3MEN1KMT2AALDH1A1MAPT
SCHEMBL13006111 0.81 HRH3 (0.48) HRH3ALDH1A1L3MBTL3L3MBTL1PKM
SCHEMBL3774012 0.80 L3MBTL1 (0.61) HRH3MEN1KMT2AALDH1A1L3MBTL3
SCHEMBL3770368 0.80 KDM4E (0.67) HRH3MEN1KMT2AALDH1A1L3MBTL3
SCHEMBL3765288 0.80 HRH3 (0.53) HRH3MEN1KMT2AALDH1A1L3MBTL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 RHOC 3326/4885RHOA 4322/4885HRH3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.